Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions reflect a general agreement on the promising effects of pentoxifylline, with posts emphasizing its role in reducing inflammation and slowing atherosclerosis, such as mentions of higher Klotho levels and better carotid artery health. The tone is optimistic but straightforward, indicating moderate engagement among medical communities interested in advancements for diabetic and CKD patient care.
Most discussions recognize the positive findings of the study, emphasizing benefits like reduced atherosclerosis progression and increased Klotho gene expression.
Participants show moderate interest, as they highlight key results and potential clinical relevance but do not delve deeply into methodological details.
There is some engagement with the content, including sharing positive reactions and referencing specific outcomes like inflammation reduction.
The social discussions suggest that the findings could influence clinical practice, highlighting PTF's potential for improving cardiovascular health in high-risk patients.
Happy to share the results of this clinical trial in which pentoxifylline reduced atherosclerosis progression in patients with diabetes and CKD, a beneficial effect related to Klotho gene expression. https://t.co/8Qcti1Wrjs @SaludISCIII @SENefrologia @SanidadGobCan @ITB_ULL
Pentoxifylline ameliorates subclinical atherosclerosis progression in patients with type 2 ... - https://t.co/gm9WpLkfcf #GoogleAlerts
RT @Javi_Donate: Happy to share the results of this clinical trial in which pentoxifylline reduced atherosclerosis progression in patients…
RT @Javi_Donate: Happy to share the results of this clinical trial in which pentoxifylline reduced atherosclerosis progression in patients…
Pentoxifylline slows atherosclerosis progression in diabetic kidney disease patients by boosting Klotho gene expression and reducing inflammation!
RT @Javi_Donate: Happy to share the results of this clinical trial in which pentoxifylline reduced atherosclerosis progression in patients…
A controlled study with 102 adult patients with diabetes and moderate to severe kidney disease found that pentoxifylline slows the progression of subclinical atherosclerosis, offering a promising therapeutic strategy to…
Pentoxifylline helps slow subclinical atherosclerosis progression in type 2 diabetes and chronic kidney disease by reducing inflammation and increasing protective proteins like Klotho, improving cardiovascular health.
Los médicos están abiertos a recibir información comercial de productos y servicios que les han aportado información para su práctica diaria. NOTIMED. La pentoxifilina podría reducir riesgo cardiovascular en pacientes con diabetes y enfermedad renal. https://t.co/3rAYELNDQS
Pentoxifylline slows atherosclerosis progression in diabetic kidney disease patients by boosting Klotho gene expression and reducing inflammation!
RT @Javi_Donate: Happy to share the results of this clinical trial in which pentoxifylline reduced atherosclerosis progression in patients…
RT @Javi_Donate: Happy to share the results of this clinical trial in which pentoxifylline reduced atherosclerosis progression in patients…
RT @Javi_Donate: Happy to share the results of this clinical trial in which pentoxifylline reduced atherosclerosis progression in patients…
RT @Javi_Donate: Happy to share the results of this clinical trial in which pentoxifylline reduced atherosclerosis progression in patients…
Happy to share the results of this clinical trial in which pentoxifylline reduced atherosclerosis progression in patients with diabetes and CKD, a beneficial effect related to Klotho gene expression. https://t.co/8Qcti1Wrjs @SaludISCIII @SENefrologia @SanidadGobCan @ITB_ULL
Pentoxifylline ameliorates subclinical atherosclerosis progression in patients with type 2 ... - https://t.co/gm9WpLkfcf #GoogleAlerts
Pentoxifylline ameliorates subclinical atherosclerosis progression in patients with type 2 diabetes and chronic kidney disease: a randomized pilot trial https://t.co/No88rO3X8l